《大行》里昂升劲方医药(02595.HK)目标价至61.9元 评级“跑赢大市”

阿斯达克财经
Mar 26

里昂发表研究报告,劲方医药-B(02595.HK) 去年收入按年升24.4%及净亏损17.95亿元人民币,均优于市场预期。G12D GFH375已进入胰脏癌注册试验阶段,而pan-RAS GFH276有望成为劲方医药的长期增长动力。GFH276的I期剂量递增试验中已观察到积极的安全性讯号。该行指,将公司今年和明年盈利预测上调4%及5.3%,其目标价由60.8元上调至61.9元,维持其评级为“跑赢...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10